Foxo Technologies has terminated Jon Sabes, its founder, chief executive and chairman of the board, two months after going public.
The Minneapolis-based company's decision, announced Tuesday, is one in a series of sudden executive changes and setbacks. It also terminated chief operating officer Steven Sabes, the CEO's brother, and announced the recent resignation of chief product officer Erin Sharoni.
On Monday, Foxo postponed the release of its third quarter financial report, scheduled for later that day.
Foxo went public in September after completing a merger with Houston-based Delwinds Insurance Acquisition Corp., a special purpose acquisition company (SPAC). Delwinds' stock was listed on the New York Stock Exchange up until the merger, trading at more than $8 a share the day it combined with Foxo.
Since its public debut, Foxo's stock has trended downward, trading at less than $1 a share since October 18. On Tuesday, it closed at 49 cents, down 12.8% on the news of the management changes. The stock closed at less than 46 cents a share on Wednesday.
Foxo's main product is a saliva test used to gather epigenetic and biological aging information. That "longevity research" material can be sold to life insurance companies that are underwriting policies.
On Wednesday, Connecticut-based Kons Law Firm issued a statement inviting shareholders to join a proposed class action lawsuit over investment losses.
Foxo is still a startup. For 2021, it posted a net loss of $38.5 million.